







an Open Access Journal by MDPI

Pediatric Infectious Disease and Vaccination

Guest Editor:

Dr. Leyla S. Namazova-Baranova

1. Pediatric Department of Pediatric Faculty, Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia 2. Central Clinical Hospital of the Russian Academy of Sciences, Moscow, Russia

Deadline for manuscript submissions:

closed (31 May 2023)

Message from the Guest Editor

Dear Colleagues,

Historically, infections have been one of the major causes of childhood morbidity and mortality. Therefore, an increasing number of studies have paid attention to diphtheria, infant diarrheal illnesses. tuberculosis. streptococcal infections and their complications, and other pediatric infections, and substantial progress has been made. However, the many remaining challenges related to infectious diseases in children (including HIV, emerging antimicrobial infections. resistance, opportunistic infections, and infections in the developing world) mean that there is still much progress to be made. The genomic era of medicine and the tools of molecular biology will lead to new insights into the pathogenesis, diagnosis, and treatment of infections, contributing to improved health for children

This Special Issue aims to attract experts in the specific field of childhood infectious diseases, and contribute to curing such infectious diseases and to the improvement of public health by fostering a better understanding of infectious disease prevention and treatment in children.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with <u>article processing charges (APC)</u> paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us